7072 Background: One of the problems in chemotherapeutical agents administration is the renal failure. In general, when the grade of creatinine (and glomerular filtration data [GFR]) is of high level, chemotherapy is avoided in nearly all the cytotoxic agents or doses are reduced. Liposomal Cisplatin is a new agent, which has been tested in phase I, II, III trials and has shown no renal toxicity.
... [Show full abstract] In the present trial this agent was tested as a single agent and also in combination with gemcitabine mainly in lung and bladder cancer patients with renal insufficiency. Methods: 40 patients, with NSCLC 16 patients, bladder 14 and 10 with GT tract, were included. 36 were men and 4 women. Median age 65 (range 40-78). Gemcitabine was given at a dose of 1000 mg/m2 and Liposomal cisplatin 150-200 mg/m2 the first day, repeated every 2 weeks. Blood urea and serum creatinine were tested before each course of treatment and 1 week after. Full blood count was also tested the same dates. The number of courses were 6 the me...
